News
05-19-2011, 03:52 AM
AstraZeneca announced today encouraging results from a phase II study in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) who had received maintenance treatment with the investigational drug olaparib, after the completion of chemotherapy.
More... (http://www.news-medical.net/news/20110519/AstraZeneca-announces-encouraging-results-from-olaparib-phase-II-study-in-serous-ovarian-cancer.aspx)
More... (http://www.news-medical.net/news/20110519/AstraZeneca-announces-encouraging-results-from-olaparib-phase-II-study-in-serous-ovarian-cancer.aspx)